SKQ1

SKQ1 is a mitochondrial-targeted antioxidant with the high mitochondrion membrane penetrating ability and potent antioxidant capability^[1]. In Vitro:Direct treatment of tumor infiltrating leukocytes with SkQ1 does not influence their cytotoxicity against Panc02 cells. While SkQ1 does not affect viability of the cell lines, this drug at 500 nM concentration reduces heavily the proliferation of human PDAC cells^[1]. In Vivo:Regarding systemic angiogenic factors, it is observed in serum of Pancreatic ductal adenocarcinoma (PDAC) bearing mice a decrease in KC in the group of continuous treatment with SkQ1. Treatment of the mice with SkQ1 increases the level of VEGF molecules. The amount of MIP1a and prolactin is reduced in all SkQ1 treatment groups or after the follow-up treatment, respectively. Also, an increase in the IL-6 and IL-13 amount is found in the SkQ1 treated groups. TGF-b amount is decreased in the pretreatment setting. On the contrary, all schemes of the SkQ1 treatment decrease the NKT cell percentage. The SkQ1 treatment has prolonged the median survival of PDAC-bearing mice, but the difference does not reach the level of significance defined^[1].